Bernstein Liebhard LLP Announces Investigation of Acquisition of Martek Biosciences Corporation by DSM

Bernstein Liebhard LLP is investigating whether the Board of Directors of Martek Biosciences Corporation (“Martek” or the “Company”) (NASDAQ: MATK) breached its fiduciary duty to its shareholders in agreeing to sell Martek to DSM.

Under the terms of the agreement, Martek shareholders will receive $31.50 in cash for each share they own. The investigation is focused on the potential unfairness of the price to Martek shareholders and the process by which the Martek Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as a Martek shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at [phone] or [e-mail].

Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered almost $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last eight years.

Bernstein Liebhard LLP10 East 40th StreetNew York, New York 10016(877) 779-1414www.bernlieb.com

ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, [phone]. Prior results do not guarantee or predict a similar outcome with respect to any future matter.